+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

2019 Medullary Thyroid Cancer Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767908
  • Report
  • 98 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Eisai Co Ltd
  • Exelixis Inc
  • Ipsen SA
  • Novartis AG
  • MORE
The global clinical trial report- “2019 Medullary Thyroid Cancer Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Medullary Thyroid Cancer. It presents in-depth analysis of Medullary Thyroid Cancer clinical trials across markets and companies. The research work is for providing complete understanding into trends in Medullary Thyroid Cancer.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Medullary Thyroid Cancer clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Medullary Thyroid Cancer

The research work is prepared through extensive and continuous research on Medullary Thyroid Cancer trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Medullary Thyroid Cancer patients are identified
  • The report includes panorama of Medullary Thyroid Cancer clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Medullary Thyroid Cancer clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Eisai Co Ltd
  • Exelixis Inc
  • Ipsen SA
  • Novartis AG
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Medullary Thyroid Cancer Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Medullary Thyroid Cancer Clinical Trials by Region
2.2.2 Average Enrollment of Medullary Thyroid Cancer Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Medullary Thyroid Cancer Treatment, 2019

3. Region wise Medullary Thyroid Cancer Clinical Trials
3.1 Asia Pacific Medullary Thyroid Cancer Clinical Trials by Country
3.2 Europe Medullary Thyroid Cancer Clinical Trials by Country
3.3 North America Medullary Thyroid Cancer Clinical Trials by Country
3.4 Middle East and Africa Medullary Thyroid Cancer Clinical Trials by Country
3.5 South and Central America Medullary Thyroid Cancer Clinical Trials by Country

4. Medullary Thyroid Cancer Clinical Trial Trends
4.1 Start Year wise Medullary Thyroid Cancer Clinical Trials
4.2 Phase wise Medullary Thyroid Cancer Clinical Trials
4.3 Trial Status wise Medullary Thyroid Cancer Clinical Trials
4.4 Trial Type wise Medullary Thyroid Cancer Clinical Trials

5. Medullary Thyroid Cancer Average Enrollment Trends
5.1 Average Enrollment in Medullary Thyroid Cancer Trials by Year
5.2 Average Enrollment in Medullary Thyroid Cancer Trials by Phase
5.3 Average Enrollment in Medullary Thyroid Cancer Trials by Status
5.4 Average Enrollment in Medullary Thyroid Cancer Trials by Type of Trial

6. Companies Participating in Medullary Thyroid Cancer Clinical Trials
6.1 Medullary Thyroid Cancer Trials by Sponsor Type
6.2 Medullary Thyroid Cancer Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Medullary Thyroid Cancer Trials- Phase 1
7.2 Medullary Thyroid Cancer Trials- Phase 2
7.3 Medullary Thyroid Cancer Trials- Phase 3
7.4 Medullary Thyroid Cancer Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Medullary Thyroid Cancer Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Medullary Thyroid Cancer Clinical Trials and Enrolment
Figure 5: Europe - Country wise Medullary Thyroid Cancer Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Medullary Thyroid Cancer Clinical Trials and Enrolment
Figure 7: North America - Country wise Medullary Thyroid Cancer Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Medullary Thyroid Cancer Clinical Trials and Enrolment
Figure 9: Medullary Thyroid Cancer Clinical Trials by Phase
Figure 10: Medullary Thyroid Cancer Clinical Trials by Trial Status
Figure 11: Medullary Thyroid Cancer Clinical Trials by Type
Figure 12: Medullary Thyroid Cancer Clinical Trials by Sponsor Type
Figure 13: Medullary Thyroid Cancer Clinical Trials by Leading Sponsors
Figure 14: Medullary Thyroid Cancer Average Enrollment by Phase
Figure 15: Medullary Thyroid Cancer Average Enrollment by Trial Status
Figure 16: Medullary Thyroid Cancer Average Enrollment by Type
Figure 17: Medullary Thyroid Cancer- Average Enrolment by Type of Sponsors
Figure 18: Medullary Thyroid Cancer- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Medullary Thyroid Cancer Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Medullary Thyroid Cancer Clinical Trials and Enrolment
Table 5: Europe - Country wise Medullary Thyroid Cancer Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Medullary Thyroid Cancer Clinical Trials and Enrolment
Table 7: North America - Country wise Medullary Thyroid Cancer Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Medullary Thyroid Cancer Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Medullary Thyroid Cancer Average Enrollment by Phase
Table 15: Medullary Thyroid Cancer Average Enrollment by Trial Status
Table 16: Medullary Thyroid Cancer Average Enrollment by Type
Table 17: Medullary Thyroid Cancer- Average Enrolment by Type of Sponsors
Table 18: Medullary Thyroid Cancer- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie Inc
  • AstraZeneca Plc
  • Eisai Co Ltd
  • Exelixis Inc
  • Ipsen SA
  • Novartis AG
  • Pfizer Inc
  • Sanofi
  • Sino Biopharmaceutical Ltd
  • Takeda Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4767908
Adroll
adroll